Hematopoietic and mesenchymal stem cell transplantation in autoimmune diseases
Future Rheumatology · 2006
DOI: 10.2217/17460816.1.2.179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Rheumatology, 2006. Verfasst von Alan Tyndall und 1 weiteren Autor:innen. Die Arbeit nennt 77 Literaturangaben.
Abstract (Originalsprache)
In the past decade, approximately 800 patients have received a hematopoietic stem cell transplant for the treatment of a severe autoimmune disease (AD). In all AD subgroups, long-term remissions (in approximately a third of cases), relapses, nonresponse and treatment-related mortality have been seen. Controlled randomized trials in systemic sclerosis, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus are underway in Europe and the USA, as well as Phase II studies in Crohn’s disease and chronic inflammatory demyelinating polyneuropathy. Laboratory studies suggest induction of long-term remission in some cases, despite the return of full, normal immune function. Recent data suggest the potential for stem cells, such as mesenchymal cells, to have an antiproliferative, immunomodulatory and tissue protective effect in AD, similar to that seen in acute graft-versus-host disease. A program to explore this further is underway and is described in this review.
Zitieren
APA
Tyndall, A., & Dazzi, F. (2006). Hematopoietic and mesenchymal stem cell transplantation in autoimmune diseases. Future Rheumatology. https://doi.org/10.2217/17460816.1.2.179
Vancouver
Tyndall A, Dazzi F. Hematopoietic and mesenchymal stem cell transplantation in autoimmune diseases. Future Rheumatology. 2006. doi:10.2217/17460816.1.2.179
BibTeX
@article{Tyndall2006,
author = {Tyndall, Alan and Dazzi, Francesco},
title = {Hematopoietic and mesenchymal stem cell transplantation in autoimmune diseases},
journal = {Future Rheumatology},
year = {2006},
doi = {10.2217/17460816.1.2.179}
}
EUVIMED